Abstract

A REVIEW ON THE ANTI VIRAL DRUG TECOVIRIMAT PRODUCE PHARMACOLOGICAL ACTIVITY AGAINST THE MONKEYPOX (MPOX)

M. Gokulpriya* and R. Manivannan

.

Abstract

Monkey pox infection is caused by a virus of the genus ORTHOPOXVIRUS, a member of the Poxviridae family. Monkey pox virus is transmitted from individual to individual through contact with lesions, body fluids, and respiratory droplets. Monkey pox disease (MPX is currently considered a global threat after COVID 19). European Medicines Agency (EMA) approved Tecovirimat in capsule dosage form (200mg as the first treatment for MPX in january 2022. Tecovirimat was first recognized as an anti orthopoxvirus molecule in 2002 and developed by SIGA Technologies. Tecovirimat safety and pharmacokinetic parameters. The patient literature has revealed inventions related to capsule, injection, suspension, crystalline forms, amorphous form, and drug combination Tecovirimat. Cidofovir and process for preparing Tecovirimat. Tecovirimat is believed to handle the current MPX outbreak and is a new hope of biosecurity against the smallpox or orthopoxvirus related bioterrorism attack.

Keywords: Tecovirimat, orthopoxvirus, monkeypox, patents, antiviral, COVID-19.